Figure 3.

Inhibitory effect of the phospholipase C inhibitor 1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione (U73122) on AE. After 160 min of incubation (Control), 1 μmol l⁻¹ U73122 (PLC inhibitor) or 1 μmol l⁻¹ 1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-2,5-pyrrolidinedione (U73343, inactive PLC inhibitor analogue) were added and then the AE inducers N-[2-(p-bromocinnamylamino)ethyl]-5isoquinolinesulfonamide (H89; 50 μmol l⁻¹), TG (3 μmol l⁻¹), progesterone (5 μmol l⁻¹), 8-(4-Chlorophenylthio)-2'-O-methyladenosine -3′,5′-cyclic (8pCPT; 0.1 μmol l⁻¹) or antibiotic A23187 Calcium Ionophore (A23187; 10 μmol l⁻¹) were added. The values represent the mean ± standard deviation of duplicates from three experiments from three different donors. ^*P < 0.05, ^**P < 0.01, and ^***P < 0.001, significant difference compared to the corresponding control. PLC: phospholipase C; AE: acrosomal exocytosis; TG: thapsigargin.